$HRMY

Budur Kumar sold $1.5M of HRMY

Budur Kumar (CHIEF MEDICAL OFFICER) sold 33,954 shares of Harmony Biosciences Holdings, Inc. (HRMY) at an average of $42.80 ($41.98–$43.10, $1.45M total) across 4 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Budur Kumar
Published Sep 9, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HRMY
Neutral
high confidence
Mentioned
$HRMY
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HRMYNeutralLow
01

Why it matters

For trading, the main value is tracking insider behavior and potential sentiment drift. However, 10b5-1 sales are generally expected and often have limited predictive power for near-term price direction absent other catalysts.

02

Market read

A routine insider sale totaling about $1.45M is unlikely to drive a fundamental repricing by itself.

03

What to watch

The disclosure does not indicate whether the insider’s remaining stake is large relative to typical patterns, nor does it provide any new company guidance or clinical/regulatory updates.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-09-09, covering sales executed 2026-09-04 to 2026-09-08.

Background

The article is an SEC Form 4 insider transaction for Harmony Biosciences Holdings, reported as an open-market sale by the Chief Medical Officer under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$HRMYNeutralHigh confidence
Context

Harmony Biosciences Holdings insider Budur Kumar, Chief Medical Officer, sold about 33,954 shares in open-market trades totaling $1.45M under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-only and typically fades as 10b5-1 sales are expected.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and an open-market sale by an officer, without any accompanying company-specific operational or regulatory catalyst.

Market effects

Minimal, as this is company-specific insider activity with no disclosed sector-wide driver.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as a mild negative signal, especially if paired with other negative news (not present here).

Key entities

  • Harmony Biosciences Holdings, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Budur Kumar

    Chief Medical Officer who sold shares in open-market trades under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2